Ukr.Biochem.J. 2013; Volume 85, Issue 3, May-Jun, pp. 10-21


Biological role of fetuin A and its potential importance for prediction of cardiovascular risk in patients with type 2 diabetes mellitus

M. Yu. Gorshunska1, Y. I. Karachentsev1,2, N. A. Kravchun2, E. Jansen3,
Zh. A. Leshchenko2, A. I. Gladkih2, N. S. Krasova2,
T. V. Tyzhnenko2, Y. A. Opaleyko2, V. V. Роltorak2

1Kharkiv Postgraduate Medical Academy,Ukraine;
2SI V. Danilevsky Institute of Endocrine Pathology Problems,
National Academy of Medical Sciences of Ukraine, Kharkiv;
3National Institute for Public Health and the Environment,
Bilthoven, Netherlands;

The authors’ data and those from literature concerning biological role of fetuin A glycoprotein have been generalized in the article. A direct correlation has been established between fetuin A and some adipokines involved in the formation of insulin resistance and atherogenesis (progranu­lin, omentin-1), and osteoprotegerin (the novel cardiovascular risk factor) as well as an increase of circulating levels of fetuin A in patients with type 2 diabetes mellitus with high cardiovascular risk metabolic pattern but without manifestations of macrovascular complications. This substantiates the involvement of fetuin A in the complex of biomarkers of subclinical atherosclerosis.

Keywords: , , , , ,


  1. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 Nov 15;376(Pt 1):135-45. PubMed, PubMedCentral, CrossRef
  2. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005 Mar 18;4(1):4. PubMed, PubMedCentral, CrossRef
  3.  Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8;361(9360):827-33. PubMed, CrossRef
  4. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007 May 15;115(19):2533-9.  PubMed, PubMedCentral, CrossRef
  5. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res. 2011 Jun 10;108(12):1494-509. PubMed, CrossRef
  6.  Daveau M, Christian-Davrinche, Julen N, Hiron M, Arnaud P, Lebreton JP. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett. 1988 Dec 5;241(1-2):191-4. PubMed, CrossRef
  7.  Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, Yang H, Gong X, Eissa NT, Jahnen-Dechent W, Wang P, Tracey KJ, Sama AE, Wang H.  A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One. 2011 Feb 8;6(2):e16945. PubMed, PubMedCentral, CrossRef
  8. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997 Mar 6;386(6620):78-81. PubMed, CrossRef
  9. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003 Apr 11;278(15):13333-41. PubMed, CrossRef
  10. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008 Mar 12;3(3):e1765. PubMedPubMedCentralCrossRef
  11. Rauth G, Pöschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Häring HU, Nawratil P, Haasemann M, Jahnen-Dechent W., Muller-Esterl W. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem. 1992 Mar 1;204(2):523-9. PubMed, CrossRef
  12.  Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, Grunberger G. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000 Jun;164(1-2):87-98. PubMed, CrossRef
  13.  Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 1997;61(16):1583-92. PubMed, CrossRef
  14.  Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002 Aug;51(8):2450-8. PubMed, CrossRef
  15. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006 Nov 17;350(2):437-43. PubMed, CrossRef
  16. Cintrón VJ, Ko MS, Chi KD, Gross JP, Srinivas PR, Goustin AS, Grunberger G. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res. 2001;1(4):249-63. PubMedPubMedCentral, CrossRef
  17. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes. 2005 Aug;54(8):2477-81.  PubMed, CrossRef
  18. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren CM, Kere J, Arner P. alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia. 2004 Nov;47(11):1974-9. PubMed, CrossRef
  19. Schmidt W, Pöll-Jordan G, Löffler G. Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP. J Biol Chem. 1990 Sep 15;265(26):15489-95. PubMed
  20. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006 Apr 11;113(14):1760-7. PubMed, PubMedCentral, CrossRef
  21.  Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care. 2006 Feb;29(2):468. PubMed, CrossRef
  22. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, Machicao F, Fritsche A, Häring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006 Apr;29(4):853-7. PubMed, CrossRef
  23.  Ix JH, Wassel CL, Chertow GM, Koster A, Johnson KC, Tylavsky FA, Cauley JA, Cummings SR, Harris TB, Shlipak MG; Health Aging and Body Composition Study. Fetuin-A and change in body composition in older persons. J Clin Endocrinol Metab. 2009 Nov;94(11):4492-8. PubMedPubMedCentral, CrossRef
  24. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008 Nov;93(11):4479-85. PubMed, CrossRef
  25. Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010 Nov;95(11):4877-81.  PubMed, CrossRef
  26. Blüher M, Rudich A, Klöting N, Golan R, Henkin Y, Rubin E, Schwarzfuchs D, Gepner Y, Stampfer MJ, Fiedler M, Thiery J, Stumvoll M, Shai I. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care. 2012 Feb;35(2):342-9. PubMed, PubMedCentral , CrossRef
  27. Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, Wang T, Wu Y, Liu Y, Li X, Chen Y, Wang W, Ning G. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011 Apr 27;6(4):e19228. PubMedPubMedCentral, CrossRef
  28. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG; Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008 Jul 9;300(2):182-8. PubMed, PubMedCentral, CrossRef
  29. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008 Oct;57(10):2762-7.
  30. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996 Apr 16;221(2):286-9. PubMed, CrossRef
  31. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001 Aug;7(8):947-53. PubMed, CrossRef
  32.  Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002 Nov;8(11):1288-95.  PubMed, CrossRef
  33. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002 Nov 26;106(22):2767-70. PubMed, CrossRef
  34. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004 Jun;344(1-2):1-12. Review. PubMed, CrossRef
  35.  Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008 Mar;114(5):361-74. Review. PubMed, CrossRef
  36. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003 Dec;14(6):561-6. Review. PubMed, CrossRef
  37. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001 May;86(5):1930-5. PubMed, CrossRef
  38. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Häring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003 Feb;52(2):239-43. PubMed, CrossRef
  39. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 Jul;116(7):1784-92. Review. PubMed, PubMedCentral, CrossRef
  40. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005 Dec;36(12):2577-82. PubMed, CrossRef
  41.  Rothenbacher D, Brenner H, März W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J. 2005 Aug;26(16):1640-6. PubMed, CrossRef
  42. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005 Feb;54(2):534-9. PubMed, CrossRef
  43. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA. 2000 Dec 19;97(26):14478-83. PubMed, PubMedCentral, CrossRef
  44. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Leprêtre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet. 2000 Dec;67(6):1470-80. PubMed, PubMedCentral, CrossRef
  45. Pollin TI, Tanner K, O’connell JR, Ott SH, Damcott CM, Shuldiner AR, McLenithan JC, Mitchell BD. Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. Diabetes. 2005 Jan;54(1):268-74. PubMed, CrossRef
  46. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 1989 Dec;38(12):1595-601. PubMed, CrossRef
  47. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995 Jan;95(1):158-66. PubMed, PubMedCentral, CrossRef
  48.  Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996 Aug 23;271(34):20789-96. PubMed, CrossRef
  49. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem. 2002 Feb 8;277(6):3926-34. PubMed, CrossRef
  50. Ix JH, Barrett-Connor E, Wassel CL, Cummins K, Bergstrom J, Daniels LB, Laughlin GA. The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. J Am Coll Cardiol. 2011 Nov 29;58(23):2372-9. PubMed, PubMedCentral, CrossRef
  51. Ix JH, Katz R, de Boer IH, Kestenbaum BR, Peralta CA, Jenny NS, Budoff M, Allison MA, Criqui MH, Siscovick D, Shlipak MG. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2012 May;58(5):887-95. PubMed, CrossRef
  52. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1618-22. PubMed, CrossRef
  53. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation. 2001 Feb 27;103(8):1051-6. PubMed, CrossRef
  54.  Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation. 1993 Apr;87(4):1179-87. PubMed, CrossRef
  55. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW; Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007 Jul;72(2):202-7. PubMed, CrossRef
  56. Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP. Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol. 2010 Jun 15;105(12):1666-72. Epub 2010 Apr 27. PubMed, CrossRef
  57. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008 Dec 9;118(24):2555-62. Epub 2008 Nov 24. PubMed, CrossRef
  58. Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010 Jun;59(6):873-8. PubMedCrossRef
  59. Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER 3rd, Reilly MP. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010 Feb;33(2):408-10. PubMed, PubMedCentral, CrossRef
  60. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 Mar;67(3):1070-7. PubMed, CrossRef
  61. Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, Joost HG, Häring HU, Hubner N, Boeing H, Weikert C. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet. 2009 Dec;2(6):607-13. PubMed, CrossRef
  62. Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, Koppensteiner R, Schernthaner GH. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011 Jan;34(1):156-61. PubMed, PubMedCentral, CrossRef
  63. Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, Scher LA, Friedman SG, Tracey KJ. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock. 2001 Mar;15(3):181-5. PubMed, CrossRef
  64.  Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Bárány P, Snaedal S, Heimbürger O, Lindholm B, Suliman ME. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest. 2008 Nov;38(11):804-11. PubMed, CrossRef
  65. Ogawa W, Kasuga M. Cell signaling. Fat stress and liver resistance. Science. 2008 Dec 5;322(5907):1483-4. PubMed, CrossRef
  66. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, Bhattacharya S. NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J. 2010 Aug 1;429(3):451-62. PubMed, CrossRef
  67. Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, Nishizawa Y. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010 Aug;21(5):281-5. PubMed, CrossRef
  68. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008 May;29(10):1307-15. PubMed, CrossRef
  69. Viezeliene D, Jansen E, Rodovicius H, Kasauskas A, Ivanov L. Protective effect of selenium on aluminium-induced oxidative stress in mouse liver in vivo. Environ Toxicol Pharmacol. 2011 Mar;31(2):302-6. PubMed, CrossRef
  70. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. PubMed, CrossRef
  71. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10. PubMed, CrossRef
  72. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf). 2007 Feb;66(2):246-50. PubMed, CrossRef
  73. Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M. The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2010 May 15;9:18. PubMed, PubMedCentral, CrossRef
  74. Reinhard H, Hansen PR, Persson F, Tarnow L, Wiinberg N, Kjær A, Petersen CL, Winther K, Parving HH, Rossing P, Jacobsen PK. Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant. 2011 Oct;26(10):3242-9. PubMed, CrossRef
  75. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006 May 2;47(9):1850-7.  PubMed, CrossRef
  76. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008 Nov;159(5):603-8. Review. PubMed, CrossRef
  77. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care. 2010 Dec;33(12):2561-6. PubMed, PubMedCentral, CrossRef
  78. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309-19. PubMed, CrossRef
  79. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998 Jun 5;273(23):14363-7. PubMed, CrossRef
  80. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005 Mar;48(3):561-8. PubMed, CrossRef
  81. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002 Sep 3;106(10):1192-4. PubMed, CrossRef
  82. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.  Circulation. 2004 May 11;109(18):2175-80. PubMed, CrossRef
  83. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001 Feb;86(2):631-7. PubMed, CrossRef
  84. Gorshunska M. Y. Total and high molecular weight adiponectin in type 2 diabetic patients with regard to gender, glycemic control and insulin resistance level. Problemi Endokrinnoi Patologii.  2012;(2):91-107.
  85. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12(9):1260-8. PubMed, PubMedCentral, CrossRef
  86. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005 Dec 30;1732(1-3):96-102. PubMed, CrossRef
  87. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1253-61. PubMed, CrossRef
  88. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007 Jun;56(6):1655-61.  PubMed, CrossRef
  89.  Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, Randeva HS. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008 Apr;57(4):801-8. PubMed, CrossRef
  90. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010 Apr;88(1):29-33. PubMed, CrossRef
  91. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011 Apr;119(4):257-63. PubMed, CrossRef
  92. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011 Nov 22;10:103. PubMed, PubMedCentral, CrossRef
  93. Cai RC, Wei L, DI JZ, Yu HY, Bao YQ, Jia WP. Expression of omentin in adipose tissues in obese and type 2 diabetic patients. Zhonghua Yi Xue Za Zhi. 2009 Feb 17;89(6):381-4. Chinese. PubMed
  94. Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci. 2010 Jul;28(9):993-8. PubMed, CrossRef
  95. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011 Jul;93(1):21-5. PubMed, CrossRef
  96. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring). 2011 Aug;19(8):1552-9. doi: 10.1038/oby.2010.351. Epub 2011 Feb 3. PubMed, CrossRef
  97. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, Shang DY. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011 Jul;32(7):873-8. Epub 2011 May 23. PubMed, PubMedCentral, CrossRef
  98. Xie H, Xie PL, Wu XP, Chen SM, Zhou HD, Yuan LQ, Sheng ZF, Tang SY, Luo XH, Liao EY. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res. 2011 Nov 1;92(2):296-306. PubMed, CrossRef
  99. Tolkatchev D, Malik S, Vinogradova A, Wang P, Chen Z, Xu P, Bennett HP, Bateman A, Ni F. Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. Protein Sci. 2008 Apr;17(4):711-24. PubMed, PubMedCentral, CrossRef
  100. Youn BS, Bang SI, Klöting N, Park JW, Lee N, Oh JE, Pi KB, Lee TH, Ruschke K, Fasshauer M, Stumvoll M, Blüher M. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes. 2009 Mar;58(3):627-36. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.